HemoGenyx Pharmaceuticals Plc(DE:5HU0)
€8.25+0.35 (+4.43%)
DE:5HU0
HemoGenyx Pharmaceuticals Plc stock drug pipeline
€8.25
At close:+0.35 (+4.43%)
HemoGenyx Pharmaceuticals Plc (5HU0) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Anti-Flt3 Car-T Cells | Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml) | Phase I | Recruiting | Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML | Jan 10, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Anti-Flt3 Car-T Cells | Phase I | Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml) | Recruiting | Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML | Jan 10, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hemogenyx Pharmaceuticals Plc (DE:5HU0) have in its pipeline
HemoGenyx Pharmaceuticals Plc DE:5HU0 is currently developing the following drugs: Anti-Flt3 Car-T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

